Digestive Diseases and Sciences

, Volume 32, Supplement 12, pp S71–S75 | Cite as

Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories

  • C. N. William
  • G. Haber
  • J. A. Aquino


Patients with active distal proctitis received either 5-aminosalicylic (5-ASA) acid or identical placebo suppositories, 500mg t.i.d. for 6 weeks. Activity at 3 and 6 wks was assessed using a Disease Activity Index (DAI), derived from four categories: number of daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment. Each category was graded 0–3. There was thus 0–12 points scored ranging from complete remission to severe disease. A minimum score of 3 from two categories was necessary for study entry. Of 27 patients randomized, 14 received active medication and 13 placebo. Of the 14 patients, with initial mean DAI 7.1 ±1.8, 11 were in complete remission at 6 wks (78.6%). Whereas, there was no significant change in the placebo group, with initial mean DAI 7.1±1.8. An additional 6 patients with inflammatory bowel disease and 6 healthy volunteers were given99mTc-labelled 5-aminosalicylic acid suppositories. The extent of spread was limited to the rectum, and the suppositories were retained for 3 hours. There was no absorbed radioactivity. 5-ASA suppositories are safe, well-tolerated, and effective treatment for active distal proctitis.

Key Words

5-aminosalicylic acid distal proctitis 99mTc-labelled 5-ASA disease activity index 


  1. 1.
    Svartz N: Salazopyrin, a new sulphanilimide preparation. Acta Med Scand 110:577, 1942Google Scholar
  2. 2.
    Das KM, Rubin R: Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1:406–425, 1976Google Scholar
  3. 3.
    Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977Google Scholar
  4. 4.
    van Hees PAM, Baker JH, van Tongeren JHM: Effect of sulphapyridine 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study of determine the active moiety of sulphasalazine. Gut 21:632–635, 1980Google Scholar
  5. 5.
    Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 285:1012, 1982Google Scholar
  6. 6.
    Dew MJ, Harries AD, Evans N, Evans BK, Rhodes J: Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. Br Med J 287:23–24, 1983Google Scholar
  7. 7.
    Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevanat RAL: National Cooperative Crohn's Disease Study; adverse reactions to study drugs. Gastroenterology 77:870–882, 1979Google Scholar
  8. 8.
    Willoughby CP, Piris J, Truelove SC: The effect of topicalN-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 15:715–719, 1980Google Scholar
  9. 9.
    Campieri M, Lanfranachi GA, Bazzocchi G, Brignola C, Corazza G, Cortini C, Michelini M, Labo G: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 2:270–271, 1981Google Scholar
  10. 10.
    Jansens J, Geboes K, Delanote C, Vantrappen G: 5-Aminosalicylic (5-ASA) enemas are effective in patients with resistant ulcerative rectosigmoiditis. Gastroenterology 84: 1198, 1983(abstract)Google Scholar
  11. 11.
    Bondesen S, Nielsen OH, Jacobson O, Rasmussen SN, Hansen SH, Halskov S, Binder V, Hvidberg EF: 5-Aminosalicylic acid enemas in patients with active ulcerative colitis: Influence of acidity on the kinetic pattern. Scand J Gastroenterol 19:677–682, 1984Google Scholar
  12. 12.
    Dew MJ, Cardwell M, Ridwai NS, Evans BK, Rhodes J: 5-Aminosalicylic acid in serum and urine after administration of enema to patients with colitis. J Pharm Pharmacol 35:323–324, 1983Google Scholar
  13. 13.
    Theur D, Theur DE: Zur Ambulanten Diagnostik und Therapie der Colitis Ulcerosa. Fortschr Med 99:1434–1437, 1981Google Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • C. N. William
    • 1
    • 2
  • G. Haber
    • 1
    • 2
  • J. A. Aquino
    • 1
    • 2
  1. 1.Department of Medicine and Nuclear MedicineDalhousie UniversityHalifaxCanada
  2. 2.University of TorontoTorontoCanada

Personalised recommendations